



**POUR ELLE**

BRUSSELS | 20-22 MARCH 2018

**18<sup>TH</sup> GENERAL MEMBERSHIP MEETING OF THE  
REPRODUCTIVE HEALTH SUPPLIES COALITION**

# Meeting user needs with a new product category: Considerations for the future of vaginal rings

Saumya RamaRao, Heather Clark and Naomi Rijo,  
Population Council

NURHT New Horizons Panel, March 20, 2018

# The promise of vaginal rings

- ✓ Sustained release of active agent
- ✓ Vaginal application reduces side-effects
- ✓ Under woman's control
- ✓ Does not require medical equipment
- ✓ Can be provided by many HCP cadres
- ✓ Potential for many sources of supply
- ✓ Potential for MPT ring



# Rings on or close to market

Ring	Indication	Institution/ company	Regulatory status
Progering®	Contraception for lactating women	ICCR	Available in Latin America
NuvaRing®	Contraception	Merck	Available high/middle income countries
NES/EE	Contraception	Pop Council	NDA filed
Fertiring®	Hormonal therapy	ICCR / Population Council	Available in Latin America
Estring®	Hormonal therapy	Pfizer	Marketed
Femring®	Hormonal therapy	Warner Chilcott	Marketed

# Rings in development

## HIV prevention rings

- Dapivirine under Article 58 review of EMA

## Pregnancy prevention

- Nestorone/Estradiol for reduced VTEs

## Multipurpose Rings for HIV/STI/Pregnancy prevention

- 4 rings in Phase I
- 5 rings in preclinical phase




# A closer look at Population Council- developed rings

# Progesterone Vaginal Ring (PVR)

- For **postpartum lactating** women in first year postpartum
- Natural progesterone hormone safe for baby and mother
- Used continuously for 3 months
- Four rings can be used successively for up to 1 year postpartum
- Approved in 8 Latin American countries (registration planned for Mexico, Brazil, Nigeria, Senegal, Kenya, India)

# Nestorone®/Ethinyl Estradiol Contraceptive Vaginal Ring (NES/EE CVR)



# Next steps for PVR and NES/EE rings

## PVR

- Register in Nigeria, Senegal, Kenya and India
- Market entry activities in Nigeria



## NES/EE

- Secure FDA approval







# Future considerations for rings



# Social and programmatic

1. User preference
2. Platforms to reach users
3. Support for continuing use



# Health Policy and Program Analysis

- Description of package of services to support introduction
- Successes and challenges of past introduction
- Pathways to scale
- Cost and financing



# Market analysis

1. Viability of the market
2. Sustaining the market
3. Market Shaping



D Dakar - Sénégal

D Dakar - Sénégal

# Biomedical

1. Development of MPTs
2. Incorporation of human centered design
3. Effects on environment





# Thank You and Acknowledgments

## **DONOR SUPPORT**

USAID

The Bill and Melinda Gates Foundation

NICHD

## **MINISTRIES OF HEALTH**

India, Kenya, Nigeria, Senegal